Published in APMIS on May 01, 2008
Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One (2014) 1.57
Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study. J Clin Microbiol (2015) 0.76
Toxoplasma encephalitis in an allogeneic hematopoietic stem cell transplant recipient in Korea. Korean J Intern Med (2012) 0.75
Imported Disease Screening Prior to Chemotherapy and Bone Marrow Transplantation for Oncohematological Malignancies. Am J Trop Med Hyg (2016) 0.75
Toxoplasmosis encephalitis with immune-reconstitution inflammatory syndrome in an allogeneic stem cell transplant patient: a case report. Bone Marrow Transplant (2016) 0.75
Parasitic Infections in Hematopoietic Stem Cell Transplantation. Mediterr J Hematol Infect Dis (2016) 0.75
Is it toxoplasma encephalitis, HIV encephalopathy or brain tuberculoma? BMJ Case Rep (2013) 0.75
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol (2003) 5.35
How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood (2009) 2.86
Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation (2003) 2.49
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis (2011) 2.19
Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res (2005) 2.16
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood (2013) 2.04
The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood (2007) 1.96
Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 1.93
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica (2010) 1.91
Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant (2011) 1.90
Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation (2005) 1.85
No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica (2007) 1.82
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81
A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation (2004) 1.75
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood (2002) 1.71
One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant (2010) 1.69
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2013) 1.69
Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol (2008) 1.63
Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood (2002) 1.55
Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant (2011) 1.54
Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica (2006) 1.52
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma (2006) 1.52
Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol (2004) 1.52
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood (2011) 1.50
Chronic widespread pain and its comorbidities: a population-based study. Arch Intern Med (2006) 1.49
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood (2004) 1.47
Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol (2006) 1.44
Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation (2004) 1.43
The socioeconomic and psychosocial circumstances of adult long-term survivors of hematopoietic stem cell transplantation in childhood. Pediatr Transplant (2011) 1.42
Importance of genetic influences on chronic widespread pain. Arthritis Rheum (2006) 1.41
Premorbid predictors of chronic fatigue. Arch Gen Psychiatry (2006) 1.40
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol (2011) 1.38
Indicators of food and water security in an Arctic Health context--results from an international workshop discussion. Int J Circumpolar Health (2013) 1.38
Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells (2012) 1.36
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica (2009) 1.34
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood (2010) 1.33
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant (2011) 1.29
Physiological correlates of burnout among women. J Psychosom Res (2003) 1.29
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood (2013) 1.27
Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood (2008) 1.23
Facing the limit of resilience: perceptions of climate change among reindeer herding Sami in Sweden. Glob Health Action (2011) 1.23
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis (2012) 1.20
Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation (2009) 1.20
Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood (2004) 1.20
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biol Blood Marrow Transplant (2009) 1.19
Twin analyses of chronic fatigue in a Swedish national sample. Psychol Med (2005) 1.18
The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica (2006) 1.15
Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant (2009) 1.15
Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2008) 1.15
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood (2002) 1.14
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood (2005) 1.14
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy (2009) 1.14
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood (2010) 1.14
Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol (2002) 1.13
Chronic fatigue in a population sample: definitions and heterogeneity. Psychol Med (2005) 1.12
KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol Immunol (2005) 1.10
A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J Virol Methods (2003) 1.09
The gender perspective in climate change and global health. Glob Health Action (2010) 1.07
Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis (2012) 1.07
Identification of species of viridans group streptococci in clinical blood culture isolates by sequence analysis of the RNase P RNA gene, rnpB. J Infect (2008) 1.06
DNA extraction and PCR assays for detection of Toxoplasma gondii. APMIS (2004) 1.06
Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuroimage (2002) 1.05
Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation (2004) 1.05
ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant (2005) 1.04
Streptococcus viridans septicaemia: a comparison study in patients admitted to the departments of infectious diseases and haematology in a university hospital. Scand J Infect Dis (2002) 1.03
A low body mass index is correlated with poor survival after allogeneic stem cell transplantation. Haematologica (2003) 1.02
The European LeukemiaNet: achievements and perspectives. Haematologica (2010) 1.02
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol (2005) 1.02
Viral infections in immunocompromised patients. Biol Blood Marrow Transplant (2011) 1.01
Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis (2009) 1.01
The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica (2006) 1.01
Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation (2003) 1.00
Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum. Transplantation (2007) 0.99
Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT). Acta Paediatr (2008) 0.99
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood (2002) 0.99
Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One (2011) 0.99
Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation. Haematologica (2014) 0.99
The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J (2012) 0.99
Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. J Clin Oncol (2002) 0.98
Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation (2008) 0.97
Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2002) 0.96
HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother (2009) 0.96
Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 0.96
Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant (2004) 0.96
Costs of allogeneic hematopoietic stem cell transplantation. Transplantation (2006) 0.96